Trial Profile

A registrational clinical trial assessing ICP-723 in China

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zurletrectinib (Primary)
Indications Solid tumours
Focus Registrational; Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

15 Jan 2024 According to an InnoCare Pharma media release, company has been advancing the registrational trial of zurletrectinib in China and is expecting to submit the new drug application in the second half of 2024.
04 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com